| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | SGMO | Common Stock | Sale | -$6.22K | -730 | 0% | $8.52* | 24.4M | Dec 1, 2021 | By Biogen MA Inc. | F1, F2 |
| transaction | SGMO | Common Stock | Sale | -$15.9K | -1.87K | -0.01% | $8.51* | 24.4M | Dec 2, 2021 | By Biogen MA Inc. | F2, F3 |
| Id | Content |
|---|---|
| F1 | The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.50 to $8.54, inclusive. The reporting person undertakes to provide to Sangamo Therapeutics, Inc., any security holder of Sangamo Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
| F2 | Shares are owned indirectly by Biogen Inc. and directly by its wholly-owned subsidiary Biogen MA Inc. |
| F3 | The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.50 to $8.515, inclusive. The reporting person undertakes to provide to Sangamo Therapeutics, Inc., any security holder of Sangamo Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |